Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15077305 | 0.86 | KMT2A (0.55) | DRD2MEN1KMT2ARORCALDH1A1 | |
| SCHEMBL12475302 | 0.85 | KMT2A (0.46) | MEN1KMT2AALDH1A1HPGDTACR1 | |
| SCHEMBL15078641 | 0.78 | RXFP1 (0.44) | RXFP1ALDH1A1LMNAMAPTCCR2 | |
| SCHEMBL788007 | 0.76 | SLC13A3 (0.43) | RXFP1ALDH1A1LMNAMAPTCCR2 | |
| SCHEMBL27969948 | 0.75 | SLC13A3 (0.46) | RXFP1RORCALDH1A1LMNAMAPT | |
| SCHEMBL27118826 | 0.75 | RXFP1 (0.46) | RXFP1ALDH1A1LMNAMAPTCCR2 | |
| SCHEMBL8574413 | 0.74 | MAPT (0.57) | RXFP1ALDH1A1LMNAMAPTTACR1 | |
| SCHEMBL21997347 | 0.74 | ALDH1A1 (0.55) | ALDH1A1LMNACASP3 | |
| SCHEMBL21996778 | 0.74 | POLB (0.51) | MEN1KMT2AALDH1A1MAPTCASP3 | |
| SCHEMBL14793217 | 0.73 | RXFP1 (0.44) | RXFP1RORCALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | RXFP1 147/4885DRD2 1480/4885MEN1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.